Innovating Future Medicine with mRNA Technology
SML Biopharm Co., Ltd. is a company specializing in mRNA-based vaccine and therapeutic development, established in 2021 through Professor Jae-Hwan Nam's university startup at Catholic University of Korea.
Experts with over 10 years of research experience in mRNA vaccines and immunoadjuvants have gathered to provide new treatment opportunities for patients suffering from diseases without treatments through differentiated mRNA platform technology.
Vision
Growing into a globally competitive biotech company utilizing mRNA technology, contributing to a healthy future for humanity.
Mission
Developing innovative therapeutics for various diseases with differentiated mRNA platform technology, providing new hope to patients suffering from untreatable diseases.
Jae-Hwan Nam
CEO / Professor at Catholic University of Korea
An Innovative Journey for the Future
Jae-Hwan Nam
CEO, SML Biopharm Co., Ltd.
History
Check out the growth history of SML Biopharm.
Government Grant Selected (KDCA)
Support Program for Developing mRNA Vaccines in Preparation for a Pandemic
Selection of Chungbuk Advanced Regenerative Bio Global Innovation Special Zone Project Operator
Chungcheongbuk-do, Republic of Korea
Government Grant Selected (Ministry of Health and Welfare)
Development of mRNA-Based Antibody Therapeutics for Severe Fever with Thrombocytopenia Syndrome (SFTS)
Opening of a branch office in Cheongju, Chungcheongbuk-do
Government Grant Selected (KDCA)
Preclinical Sample Production and Evaluation for Securing SFTS therapeutic candidate substance
Grant Selected Top 1000+ Next-Generation Startups
(Ministry of SMEs and Startups)
Government Grant Selected (KDCA)
SFTS Immune Candidate Non-clinical and Sample Production Condition Establishment
New headquarter and In-House Research Center Established at M Cluster by Gwangmyeong Station
Series A Funding from Meritz Securities Secured
Venture Business Status Certified
Company - Affiliated Research Laboratory Established at Catholic University of Korea
Seed Funding from Samkwang Labtree Co. Ltd. Secured
SML Biopharm Established
(Faculty Startup in the Department of Biomedical Sciences at Catholic University of Korea)
Strategic Partnerships
We collaborate with leading institutions worldwide to develop innovative therapeutics.
Probio
중국mRNA 개발·생산·임상연구 협력
CATUG
스위스mRNA 기술 개발 및 상업화 협력
Affilogic
프랑스Nanofitin 기반 표적 신약 개발
Cha Vaccine Institute
한국mRNA 기반 백신 및 치료제 공동개발!
Catholic University of Korea
한국산학협력 및 CUK-SML 의생명센터 운영
KDCA
한국SFTS 치료후보물질 개발 과제
MOHW
한국감염병 예방·치료 기술개발사업
